Compare Stocks: BCAX, KNSA, DNTH, and COGT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$22.64 +0.2%	$25.21	$10.30 ▼ $30.99	$1.49B	-0.82	489,337 shs	934,225 shs
COGT Cogent Biosciences	$31.50 -5.1%	$37.36	$11.60 ▼ $43.73	$5.76B	0.31	1.51 million shs	4.60 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
KNSA Kiniksa Pharmaceuticals International	$77.17 -2.7%	$74.58	$35.20 ▼ $82.94	$6.19B	0.09	473,868 shs	1.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+2.68%	-2.21%	-9.35%	-2.76%	+105.93%
COGT Cogent Biosciences	+2.00%	-2.61%	-11.26%	-3.91%	+168.53%
DNTH Dianthus Therapeutics	-1.34%	-2.09%	-12.48%	+22.58%	+160.08%
KNSA Kiniksa Pharmaceuticals International	+2.20%	+3.73%	-0.20%	+43.95%	+123.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$22.64 +0.2%	$25.21	$10.30 ▼ $30.99	$1.49B	-0.82	489,337 shs	934,225 shs
COGT Cogent Biosciences	$31.50 -5.1%	$37.36	$11.60 ▼ $43.73	$5.76B	0.31	1.51 million shs	4.60 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
KNSA Kiniksa Pharmaceuticals International	$77.17 -2.7%	$74.58	$35.20 ▼ $82.94	$6.19B	0.09	473,868 shs	1.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+2.68%	-2.21%	-9.35%	-2.76%	+105.93%
COGT Cogent Biosciences	+2.00%	-2.61%	-11.26%	-3.91%	+168.53%
DNTH Dianthus Therapeutics	-1.34%	-2.09%	-12.48%	+22.58%	+160.08%
KNSA Kiniksa Pharmaceuticals International	+2.20%	+3.73%	-0.20%	+43.95%	+123.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	44.15% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	63.67% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	34.11% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	13.23% Upside

Current Analyst Ratings Breakdown

Latest BCAX, KNSA, DNTH, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
9/15/2026	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/10/2026	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
DNTH Dianthus Therapeutics	$2.04M	2,594.41	N/A	N/A	$11.41 per share	8.48
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.89	$0.77 per share	99.94	$7.44 per share	10.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	79.56	37.28	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)

Latest BCAX, KNSA, DNTH, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
COGT Cogent Biosciences	0.48	13.57	13.57
DNTH Dianthus Therapeutics	N/A	26.10	26.10
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
COGT Cogent Biosciences	N/A
DNTH Dianthus Therapeutics	47.53%
KNSA Kiniksa Pharmaceuticals International	53.95%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
COGT Cogent Biosciences	6.59%
DNTH Dianthus Therapeutics	3.02%
KNSA Kiniksa Pharmaceuticals International	51.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	103	66.17 million	57.04 million	N/A
COGT Cogent Biosciences	258	173.52 million	162.09 million	Optionable
DNTH Dianthus Therapeutics	92	54.67 million	53.02 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable

BCAX, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

September 17 at 1:17 PM | zacks.com

Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

September 11, 2026 | marketbeat.com

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

September 11, 2026 | investors.com

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

September 4, 2026 | globenewswire.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares

September 3, 2026 | marketbeat.com

Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP

September 3, 2026 | marketbeat.com

Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA

September 1, 2026 | marketbeat.com

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 31, 2026 | marketbeat.com

Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA

August 19, 2026 | marketbeat.com

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

August 7, 2026 | globenewswire.com

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

August 3, 2026 | zacks.com

G Bradley Cole Sells 3,673 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

August 1, 2026 | insidertrades.com

Kiniksa Pharmaceuticals International, plc 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

July 30, 2026 | zacks.com

Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?

July 29, 2026 | finance.yahoo.com

Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline

July 29, 2026 | finance.yahoo.com

Kiniksa Pharmaceuticals Announces Q2 2026 Financial Results on July 28, 2026

July 29, 2026 | kalkinemedia.comK

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates

July 28, 2026 | zacks.com

Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.30 beats by $0.01, revenue of $243.6M beats by $17.14M

July 28, 2026 | seekingalpha.com

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

July 28, 2026 | globenewswire.com

Kiniksa Pharmaceuticals International, plc Q2 2026 earnings preview

July 27, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, KNSA, DNTH, and COGT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$22.64 +0.05 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$22.65 +0.01 (+0.04%)

As of 07:30 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Cogent Biosciences NASDAQ:COGT

$31.50 -1.69 (-5.09%)

Closing price 04:00 PM Eastern

Extended Trading

$32.14 +0.64 (+2.03%)

As of 07:30 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$96.81 -4.31 (-4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$96.82 +0.02 (+0.02%)

As of 07:30 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$77.17 -2.16 (-2.72%)

Closing price 03:59 PM Eastern

Extended Trading

$77.17 +0.00 (+0.00%)

As of 07:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, KNSA, DNTH, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, KNSA, DNTH, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, KNSA, DNTH, and COGT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Cogent Biosciences NASDAQ:COGT

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, KNSA, DNTH, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, KNSA, DNTH, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, KNSA, DNTH, and COGT Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Cogent Biosciences NASDAQ:COGT

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools